Strategic Collaboration Aims to Accelerate Radionuclide Drug Conjugates
Harbour BioMed has announced a long-term strategic collaboration with Lannacheng to accelerate the discovery and development of next-generation radionuclide drug conjugates (RDCs). The partnership combines Harbour BioMed’s expertise in antibody therapeutics with Lannacheng’s strength in radiopharmaceutical science, creating a powerful platform to target difficult-to-treat cancers and inflammatory diseases.
What RDCs Bring to the Table
Radionuclide drug conjugates leverage targeted antibodies linked to radioactive payloads, delivering precise cytotoxic radiation to disease sites while sparing healthy tissue. This approach holds promise for enhancing therapeutic efficacy, particularly in oncology, where solid tumors often resist conventional therapies. The collaboration aims to advance RDC candidates from discovery through preclinical validation and into early-stage clinical studies, with a focus on improving response rates and patient outcomes.
Balanced Expertise for Comprehensive Development
Under the agreement, Harbour BioMed will contribute its deep experience in antibody engineering, translational science, and clinical development capabilities in immunology and oncology. Lannacheng will provide its radiochemistry know-how, radiopharmacy operations, and regulatory strategy to bring RDCs from bench to bedside. The joint team intends to establish an integrated development pathway that aligns radiopharmaceutical physics with antibody targeting and therapeutic payloads, aiming to shorten timelines and reduce development risk.
Strategic Implications for Oncology and Immunology
The collaboration underscores a growing trend in biopharma toward combining biologics with radiopharmaceuticals to create highly specific, potent therapies. By uniting Harbour BioMed’s antibody technology with Lannacheng’s radiolabeling expertise, the partners expect to address solid-tumor challenges, minimize off-target toxicity, and expand the potential indications for RDCs. The alliance also positions both companies to pursue combination strategies with established immunotherapies, potentially enhancing response durability for patients in need.
Paths to Clinical Milestones
While specific program timelines remain confidential, the partners have signaled a joint roadmap that includes candidate selection, translational studies, and single- or multi-ascending-dose cohorts in early clinical trials. The collaboration emphasizes robust safety profiling, dosimetry optimization, and biomarker-driven patient selection to maximize therapeutic windows. As RDC science evolves, the alliance could unlock new opportunities for precision radiopharmaceuticals in oncology and immune-mediated diseases.
Commitment to Innovation and Patient Access
Both Harbour BioMed and Lannacheng have publicly committed to advancing innovative therapies that address unmet medical needs. This strategic collaboration reflects a broader industry focus on next-generation radiopharmaceuticals and antibody–drug conjugates, with the ultimate aim of delivering more effective and accessible treatments to patients worldwide. The companies will also explore manufacturing scalability, regulatory pathways, and global clinical development plans to support timely patient access.
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics for immunology and oncology. The company integrates cutting-edge biology with translational science to bring transformative therapies to patients while maintaining a disciplined, data-driven development approach.
About Lannacheng
Lannacheng is a leader in radiopharmaceutical innovation, providing radiochemistry expertise, regulatory guidance, and scalable radiopharmacy capabilities to advance radionuclide therapies. The company collaborates with partners to design and execute RDC programs that can improve targeted delivery and clinical outcomes.
Forward-Looking Collaboration
The collaboration represents a strategic step for both organizations as they pursue next-generation RDCs that combine precision targeting with potent radiopharmaceutical payloads. Stakeholders can expect regular updates on program milestones, scientific advancements, and potential new indications as the partnership progresses.
